
FBRX
Healthcare · Biotechnology · $1.63B market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -8.5% over 90 days · 30-day revisions 0 up, 1 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 12, 2026 | After the close | -1.08 | -0.97 | +10.2% |
| May 11, 2026 | Before the open | -1.16 | -1.24 | -6.9% |
| Nov 14, 2025 | Before the open | -1.07 | -0.99 | +7.5% |
| Aug 14, 2025 | After the close | -1.11 | -0.96 | +13.5% |
| May 15, 2025 | After the close | -0.89 | -1.37 | -53.9% |
| Mar 28, 2025 | Time not confirmed | -0.14 | -1.17 | -735.7% |
| Nov 14, 2024 | After the close | -7.12 | -4.54 | +36.2% |
| Aug 14, 2024 | After the close | -4.12 | -6.75 | -63.8% |
| May 13, 2024 | After the close | -4.25 | -4.00 | +5.9% |
| Mar 18, 2024 | After the close | -0.28 | -0.19 | +32.1% |
| Nov 13, 2023 | After the close | -0.57 | -0.26 | +54.4% |
| Aug 14, 2023 | After the close | -0.42 | -0.42 | 0.0% |
| May 15, 2023 | After the close | -0.32 |
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences,…
| -0.23 |
| +27.4% |
| Mar 31, 2023 | After the close | -0.16 | -0.23 | -43.8% |
| Nov 14, 2022 | After the close | -3.75 | -4.50 | -20.0% |
| Aug 15, 2022 | After the close | -4.75 | -5.25 | -10.5% |
| May 16, 2022 | Before the open | -0.17 | -0.17 | 0.0% |
| Mar 31, 2022 | After the close | -0.32 | -0.21 | +34.4% |
| Nov 8, 2021 | Before the open | -9.31 | -13.50 | -45.0% |
| Aug 16, 2021 | Before the open | -10.92 | -10.75 | +1.6% |
| May 10, 2021 | After the close | -12.28 | -9.00 | +26.7% |
| Mar 16, 2021 | Before the open | -0.57 | -0.37 | +35.1% |
| Nov 9, 2020 | After the close | -7.62 | -11.25 | -47.6% |
| Aug 10, 2020 | After the close | -4.50 | -18.52 | -311.6% |
| Apr 23, 2020 | After the close | -6.60 | -6.45 | +2.3% |
| Feb 27, 2020 | After the close | -8.55 | -7.50 | +12.3% |
| Nov 12, 2019 | After the close | -10.49 | -11.70 | -11.5% |
| Aug 8, 2019 | After the close | -11.34 | -10.80 | +4.8% |
| May 7, 2019 | After the close | -15.15 | -11.10 | +26.7% |
| Feb 27, 2019 | After the close | -10.26 | -14.40 | -40.4% |
| Nov 8, 2018 | After the close | -6.75 | -0.30 | +95.6% |
| Aug 7, 2018 | After the close | -8.90 | -12.15 | -36.5% |
| May 10, 2018 | After the close | -0.57 | -9.75 | -1610.5% |
| Mar 8, 2018 | After the close | -9.37 | -8.25 | +12.0% |